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Dear Editor,
Immunosuppressive therapy is the main risk factor for opportunistic infections in patients with inflammatory bowel disease (IBD) (1) . We present a thought-provoking case of an opportunistic infection, which resulted in treatment difficulties and morbidity.
Case report
A horse rider, 16-year-old female with a 2-year history of ulcerative colitis (UC) (E3 Montreal classification), while in remission with oral mesalamine, had her first mildmoderate UC flare requiring oral steroids (0.5 mg/kg). One month later, she was admitted to the hospital with a severe UC flare (Montreal classification S3, Mayo Score 12), needing intravenous steroid (1 mg/kg) treatment.
After five days, there was only a partial steroid response (Mayo Score 5). Moreover, she presented a progressively increasing cough and hemoptysis without clinical or analytical repercussions. The chest radiograph and CT showed two cavitated nodules with a peripheral halo in both lungs (Fig. 1) . Bronchoscopy and bronchoalveolar lavage demonstrated invasive pulmonary aspergillosis.
Voriconazol (4 mg/kg/12 hours) was prescribed. Steroids were tapered and leukapheresis (LCAP) was started to avoid immunosuppression. Intensive LCAP (two sessions/week during five weeks) was followed by weekly sessions and monthly sessions, finally obtaining UC remission. The patient had no cough or hemoptysis, and the pulmonary lesions shrank on CT. LCAP was maintained for six months, until voriconazol was removed.
Discussion
The risk of fungal infection in IBD seems to be low, but morbidity and mortality are high (1) . In patients with a fungal infection, immunomodulator therapy should be stopped and standard therapy for the infection implemented (2). Our case shows the relevance of a history of horse contact. The presence of Aspergillus fumigatus in the equine nasopharyngeal cavity can infect immunocompromised humans (3). This case highlights the fact that opportunistic infections in immunocompromised IBD patients require a high degree of suspicion and restrict therapeutic options. In this context, LCAP represents an effective therapeutic option for both remission and UC maintenance treatment (4) .
